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ABSTRACT
Objective Post-colonoscopy colorectal cancer (PCCRC)
is a key quality indicator of colonoscopy. This study
compares methods for deﬁning PCCRC rates, proposes a
new method of calculating them and quantiﬁes them
across the English National Health Service (NHS).
Design This retrospective observational population-
based study involved all individuals with a ﬁrst primary
diagnosis of colorectal cancer made between 2001 and
2010 and treated in the English NHS. Previously
published methods for deriving PCCRC rates were
applied to the linked routine health data for this
population to investigate the effect on the rate. A new
method, based on the year of the colonoscopy rather
than colorectal cancer diagnosis, was then used to
calculate PCCRC rates.
Results Of 297 956 individuals diagnosed with
colorectal cancer, a total of 94 648 underwent a
colonoscopy in the 3 years prior to their diagnosis. The
application of the published methods and exclusion
criteria to the dataset produced signiﬁcantly different
PCCRC rates from 2.5% to 7.7%. The new method
demonstrates that PCCRC rates within 3 years of
colonoscopy (without exclusions) decreased in the
English NHS over 8 years, falling from 10.6% to 7.3%
for colonoscopies performed in 2001 and 2007
respectively.
Conclusions The method used to determine PCCRC
rates signiﬁcantly affects ﬁndings with potential to
substantially underestimate rates. To enable international
benchmarking there needs to be a standardised method
for deﬁning PCCRC. This study proposes a new
methodology using colonoscopy as a denominator and
between 2001 and 2007 this method indicated an 8.6%
PCCRC rate across the English NHS. It also demonstrated
PCCRC rates have fallen over time.
INTRODUCTION
Colorectal cancer is a major public health problem
in the UK, with over 40 000 new cases being diag-
nosed and around 16 000 people dying from the
disease every year.1 The best survival rates for the
illness are observed in those who are diagnosed
with early stage tumours2 and, as overall survival
for the disease is relatively poor in the UK,3 4 there
is a push to identify more cancers as soon as pos-
sible.5 Optimising diagnostic services is, therefore,
a priority.
The main diagnostic test used to identify colorec-
tal cancer is colonoscopy. Unfortunately, however,
the test is not always 100% accurate. Some indivi-
duals may undergo colonoscopy which is negative
for cancer but subsequently be diagnosed with a
cancer—a post-colonoscopy colorectal cancer
(PCCRC). This may be a result of the development
of a rapidly growing new tumour that was not
present at initial colonoscopy but, more frequently,
it appears to be due to missed or inadequately
excised pre-cancerous lesions, or the colorectal
cancer simply being missed by the colonoscopist.6 7
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Signiﬁcance of this study
What is already known on the topic?
▸ Post-colonoscopy colorectal cancer (PCCRC)
rates have been proposed as a key quality
indicator of a colonoscopy service.
▸ Several methods of calculating PCCRC rates
have been published, with reported rates
varying between 2.1% and 7.5%.
▸ Little is known about PCCRC rates in the
English National Health Service (NHS).
What are the new ﬁndings?
▸ Rates of PCCRC vary considerably in relation to
the method used to deﬁne a PCCRC.
▸ The preferred methodology demonstrated a
PCCRC rate within 3 years of colonoscopy of
8.6% in the English NHS.
▸ PCCRC rates have fallen over time.
How might it impact on clinical practice in
the foreseeable future?
▸ The application of a PCCRC indicator for
colonoscopy providers based on routine linked
NHS data offers a practical method for
assessing the quality of the services delivered.
▸ For international benchmarking an agreed
method for deﬁning PCCRC rate is required.
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The rate of PCCRC occurrence has been proposed, therefore, as
a quality indicator of a colonoscopy service.
Generating a robust indicator of PCCRC rates is challenging.
Several studies have sought to quantify the occurrence of
PCCRCs and determine what factors predispose to their devel-
opment.7–17 Across these studies PCCRCs were consistently
seen to be more common in older age groups, in women, in the
proximal bowel and following colonoscopies undertaken by
non-specialist endoscopists.10 16 18 19 The reported rates of
PCCRC have varied considerably from 2.1% to 7.5% and
although this could be due to differences in the quality of colo-
noscopic services across the populations considered, it may also
be a reﬂection of the different datasets and methods used to cal-
culate the rates.
The National Cancer Data Repository (NCDR)20 contains
information on all individuals diagnosed with colorectal cancer
in England and their hospital management (including the colo-
noscopic investigations). Therefore, it enables population and
organization based investigation of patterns of PCCRCs across
the English National Health Service (NHS). This study aimed to
make use of these data to investigate how PCCRC rates vary in
relation to the method adopted to derive them, to determine
the optimal methodology to calculate PCCRC rates and, using
this technique, to investigate any variability and factors asso-
ciated with the occurrence of PCCRC across the English NHS.
METHODS
All individuals with a ﬁrst diagnosis of colorectal cancer
(International Classiﬁcation of Diseases V.10 (ICD10)22 code
C18–20) between 2001 and 2010 were identiﬁed in the NCDR.
The hospital records of these individuals were then sought to
identify all colonoscopies (codes of eligible procedures listed in
table 1) undertaken prior to their diagnosis. Two datasets were
then extracted. The ﬁrst used cancers as the denominator and
contained data on the ﬁrst primary diagnosis of colorectal
cancer in an individual made over the study period. The second
used colonoscopies as the denominator and included informa-
tion on each of the colonoscopies undertaken in individuals
who went on to have a diagnosis of colorectal cancer within
3 years of this test.
The patient-level data in both datasets included age at diagno-
sis and colonoscopy, sex, socioeconomic status (based on quin-
tiles of the income domain of the Index of Multiple
Deprivation (IMD) 2007) and Charlson comorbidity score21
(based on diagnostic reasons for hospital admissions in the year
prior to diagnosis of the cancer). In addition, all individuals
who had experienced a hospital admission for Crohn’s disease,
ulcerative colitis or diverticular disease were identiﬁed (ICD10
codes K50, K51 and K57 respectively). Tumour information
included date of diagnosis, modiﬁed Dukes’ stage of disease at
diagnosis and site of tumour based on ICD10 codes. These were
classiﬁed as rectum or sigmoid colon (ICD10 C187, C19–20),
splenic ﬂexure and descending colon (C185–6), transverse colon
(C184), right colon (C180–3) or colon not otherwise speciﬁed
(C188–9).
In both datasets the interval between each colonoscopy and
the diagnosis of the subsequent cancer was determined and
grouped into two categories. In the cancer dataset, tumours that
were diagnosed within 6 months of a colonoscopy were classed
as ‘detected’ cancers, while those diagnosed more than
6 months after the colonoscopy were classed as PCCRC. All
other cancers (in individuals with no history of colonoscopy at
the time of cancer diagnosis or in the 36 months prior to diag-
nosis) were allocated to a ‘no colonoscopy’ group. Likewise, in
the colonoscopy dataset, colonoscopies following which a
cancer was diagnosed within 6 months were identiﬁed as true
positive colonoscopies and those in which a cancer was diag-
nosed greater than 6 months after the investigation were
deemed false negative colonoscopies. It is appreciated that the
terms false negative and true positive normally depend on there
being a gold standard which does not exist for the diagnosis of
colorectal cancer and its precursors. In this study it is presumed
that colonoscopy has the potential to prevent or detect all
cancers that might otherwise present within 3 years; thus the
appearance of cancer within 3 years is the gold standard.
Some individuals underwent multiple colonoscopies in the
detected and PCCRC periods. This was ﬂagged in the cancer
dataset, and only the closest colonoscopy to diagnosis in each
category was used in analyses. However, individual records for
each colonoscopy remained in the colonoscopy dataset and the
total number of colonoscopies an individual underwent in
either the true-positive or false-negative category was noted.
Four previously published population-based methods for
deriving PCCRC rates had used the total number of individuals
with cancers as the denominator.7 10 11 16 The methods
adopted were discussed with the authors of three papers before
application to this cancer dataset.7 10 16 These different
methods had all made exclusions from their study populations
(as detailed in ﬁgure 1) and so, if possible, individuals in our
study population who would have been excluded following
these methods were identiﬁed and ﬂagged. Due to the data
available in the NCDR it was not possible, however, to apply all
the criteria for all the methods. PCCRC rates were then derived
based on the four different methods described below and in
ﬁgure 1.
Bressler method10
This method deﬁned PCCRCs as those that occurred in indivi-
duals who had a colonoscopy 6–36 months prior to diagnosis of
their colorectal cancer but who did not have a colonoscopy
within 6 months of their diagnosis. This approach effectively
precluded any patients diagnosed with colonoscopy being desig-
nated as PCCRC. Thus only cancers diagnosed with other
methods could be labelled as PCCRC. The PCCRC rate was
deﬁned as the number of PCCRCs divided by the total number
of individuals with a cancer who underwent any colonoscopy
prior to diagnosis.
Cooper method11
This method deﬁned PCCRCs as all those that occurred
6–36 months prior to diagnosis of colorectal cancer in indivi-
duals irrespective of whether their tumour was subsequently
identiﬁed by a colonoscopy. Again, the PCCRC rate was deﬁned
as the number of PCCRCs divided by the total number of indi-
viduals with a cancer who underwent any colonoscopy in the
36 months prior to diagnosis.
Table 1 OPCS4 codes used to identify a colonoscopy
OPCS4 code Description
G79 Therapeutic operations on ileum
G80 Diagnostic endoscopic examination of ileum
H20 Endoscopic extirpation of lesion of colon
H21 Other therapeutic endoscopic operations on colon
H22 Diagnostic endoscopic examination of colon
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Singh method16
Like Cooper et al, this method deﬁned PCCRCs as all those
that occurred 6–36 months prior to diagnosis of colorectal
cancer in individuals irrespective of whether their tumour was
subsequently identiﬁed by colonoscopy. But the method also
allowed cancers to be counted in both the PCCRC and detected
categories so if an individual underwent two colonoscopies, one
in the 6 months prior to diagnosis and another in the 6–
36 month period, a PCCRC and a detected cancer were
included in the rate calculation. The denominator was all
PCCRCs plus all detected cancers.
Le Clercq method7
This method deﬁned a PCCRC in the same way as Cooper and
Singh but used all individuals with cancer, rather than just those
who had a colonoscopy prior to, or at, diagnosis, as the
denominator.
New colonoscopy method
The colonoscopy dataset was then analysed using a new method
which changed the denominator from cancers to colonoscopies.
The purpose of creating this new method was to have a measure
that was most relevant to patients having a colonoscopy (not to
those who have a cancer) by creating a measure based on the
number of colonoscopies, not cancers. It is presumed that
patients who have a cancer currently, or are destined to develop
one in the next 3 years, would like to know the likelihood the
cancer is missed or not prevented by the current colonoscopy.
On the basis of this presumption the proposed PCCRC rate uses
the appearance of cancer over 3 years as the gold standard: the
true positives plus the false negatives. The PCCRC rate is
deﬁned simply as the number of false-negative colonoscopies
divided by the gold standard. For individuals who underwent
multiple colonoscopies only the ﬁrst true-positive and ﬁrst false-
negative colonoscopy was included in this calculation.
Trends in PCCRC rates in relation to the year of colonoscopy
were investigated. The follow-up time in which a cancer could
be diagnosed for colonoscopies undertaken at the beginning of
the cohort was greater than for those undertaken at the end.
Prior to investigating the characteristics of PCCRC and detected
cancers using this method the data were, therefore, censored to
include only those that occurred within 3 years of the initial
colonoscopy.
Multilevel (random effects) logistic regression models were
built to determine factors associated with the occurrence of a
PCCRC. These models were built with a hierarchy of colonos-
copies clustered within individuals. The dependent variable was
the occurrence of a PCCRC and the explanatory variables were
year of colonoscopy, age at colonoscopy (per year increase), sex
of individual, site of tumour, IMD23 income category at diagno-
sis, and prior in-patient hospital admission for Crohn’s disease,
ulcerative colitis and diverticular disease.
Finally, the statistical analysis was restricted to cancers appear-
ing within 36 months of a colonoscopy. The data (for colonos-
copies performed up to the end of 2005 only) were further
analysed to 60 months to determine whether new PCCRCs con-
tinue to form 2–5 years after a colonoscopy.
RESULTS
Between 1 January 2001 and 31 December 2010, 297 956 indi-
viduals in England were identiﬁed within the NCDR as being
diagnosed with a ﬁrst primary colorectal cancer. Within this
Figure 1 Application and results of four previously published methods for determining post-colonoscopy colorectal cancer (PCCRC). Note: the
original le Clercq study calculated PCCRCs over a 0–60-month time period whereas all the other studies used the period of 0–36 months. In the
interests of consistency and to enable more ready comparison of methods, in this particular study, the le Clercq method has been simpliﬁed to
calculate PCCRCs covering a period of 0–36 months too.
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population, 94 648 (31.7%) individuals had a record of a colon-
oscopy within the 3 years prior to their diagnosis. Of these
cancers, 90 398 had one or more colonoscopies in the 6 months
prior to diagnosis and 7321 had a colonoscopy within the 36 to
6 months preceding diagnosis. This population forms the basis
of the cancer dataset used to compare the previously published
methods, and its characteristics are described in table 2.
The process and results of the application of the four previ-
ously published methods of determining PCCRC rates is shown
in ﬁgure 1. Using the Bressler method, but without any exclu-
sions, 4250 of these cancers were classed as PCCRC leading to
a 4.5% PCCRC rate. In contrast, both the Cooper and Singh
methods increased the number of cancers classed as PCCRC to
7321 but, due to the differences in how the denominator was
derived for each method, the PCCRC rates were 7.7% and
7.5% respectively. The le Clercq method also identiﬁed 7321
PCCRCs but the denominator included all cancers diagnosed in
the study region, irrespective of whether they were diagnosed
by colonoscopy or another method. This signiﬁcantly increased
the denominator and so reduced the PCCRC rate to 2.5%. The
rates derived by each of these methods following the application
of the original exclusion criteria used in the studies are, again,
shown in ﬁgure 1. Signiﬁcant variation was observed in rates
(2.5–6.8%) depending on the exclusion criteria adopted.
The data in the colonoscopy dataset had a different structure
as it used colonoscopy as the denominator. Therefore, it con-
tained information on the 61 633 colonoscopies undertaken
between 2001 and 2007 in the 57 963 individuals who went on
to be diagnosed with a colorectal cancer within 3 years of their
investigation. Of these colonoscopies 55 539 were true positive
Table 2 Characteristics of the cancers diagnosed between 2001 and 2010 in relation to colonoscopy category
Cancers occurring
>6 months after
colonoscopy
≤6 months after
colonoscopy
With any
colonoscopy Without colonoscopy
Characteristic n % n % n % n % All cancers
Median age at diagnosis (IQR) 73 (65–80) 72 (64–79) 73 (64–81) 72 (64–79) 73 (64–80)
Sex
Male 3900 2.4 51 545 31.6 53 680 32.9 109 649 67.1 163 329
Female 3421 2.5 38 853 28.9 40 968 30.4 93 659 69.6 134 627
IMD income category at diagnosis
Most affluent 1532 2.5 18 954 31.1 19 815 32.5 41 085 67.5 60 900
2 1553 2.4 19 656 30.1 20 543 31.5 44 704 68.5 65 247
3 1473 2.3 19 241 30.3 20 113 31.6 43 437 68.4 63 550
4 1484 2.5 17 682 30.2 18 540 31.7 39 979 68.3 58 519
Most deprived 1279 2.6 14 865 29.9 15 637 31.4 34 103 68.6 49 740
Charlson comorbidity score at diagnosis
0 4497 2.2 62 794 30.2 65 363 31.4 142 892 68.6 208 255
1 1284 3.1 13 681 32.7 14 444 34.5 27 457 65.5 41 901
2 926 3.0 9459 30.9 9989 32.7 20 576 67.3 30 565
≥3 614 4.3 4464 31.4 4852 34.1 9362 65.9 14 214
Unknown 0 0.0 0 0.0 0 0.0 3021 100.0 3021
Previous hospital admission for Crohn’s disease
No 6987 2.4 89 561 30.3 93 639 31.6 202 286 68.4 295 925
Yes 334 16.4 837 41.2 1009 49.7 1022 50.3 2031
Previous hospital admission for ulcerative colitis
No 6493 2.2 88 736 30.2 92 584 31.5 201 670 68.5 294 254
Yes 828 22.4 1662 44.9 2064 55.8 1638 44.2 3702
Previous hospital admission for diverticular disease
No 4380 1.9 63 230 26.8 65 822 27.9 170 200 72.1 236 022
Yes 2941 4.7 27 168 43.9 28 826 46.5 33 108 53.5 61 934
Dukes’ stage at diagnosis
A 1113 3.8 12 865 44.3 13 340 45.9 15 718 54.1 29 058
B 1517 2.1 25 474 35.5 26 205 36.5 45 534 63.5 71 739
C 1496 2.1 23 193 32.3 24 030 33.5 47 797 66.5 71 827
D 995 2.1 10 402 22.4 11 086 23.8 35 428 76.2 46 514
Unknown 7321 9.3 18 464 23.4 19 987 25.4 58 831 74.6 78 818
Tumour site
Rectal/sigmoid colon 2926 1.7 46 552 27.6 48 372 28.6 120 518 71.4 168 890
Splenic flexure/descending colon 289 2.1 4331 31.2 4452 32.1 9409 67.9 13 861
Transverse colon 398 3.0 5039 38.3 5212 39.6 7945 60.4 13 157
Right colon 2679 3.7 29 001 39.8 30 359 41.7 42 530 58.3 72 889
Colon NOS 1029 3.5 5475 18.8 6253 21.4 22 906 78.6 29 159
Total 7321 2.5 90 398 30.3 94 648 31.8 203 308 68.2 297 956
IMD, Index of Multiple Deprivation; NOS, not otherwise specified.
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and 6094 false negative. When only the colonoscopy closest to
diagnosis was included for an individual with multiple investiga-
tions in either or both the true-positive and false-negative cat-
egories, these numbers reduced to 52 992 and 4971
respectively. The characteristics of this population are shown in
table 3. The number of cancers diagnosed by colonoscopy
increased signiﬁcantly over time (ﬁgure 2), in keeping with the
improved access to colonoscopy and the increase in colonoscopy
activity over these years. Cancers arising following false-negative
colonoscopies were signiﬁcantly more common in women, in
the right colon and in those with greater comorbidity.
The new method to determine PCCRC rates in a number
of time intervals after colonoscopy undertaken in each
calendar year was then applied. For example, for colonos-
copy undertaken in 2001 there were 5281 investigations that
led to a detected cancer and so were deemed a ‘true-positive’
colonoscopy. But in the 6–12 months following colonos-
copies in this year, 204 cancers were diagnosed, indicating
204 false-negative colonoscopies. The rate of PCCRC at this
time point was, therefore, 204 divided by 5485 (the total of
true-positive (5281) and false-negative (204) colonoscopies),
giving a PCCRC rate of 3.7%. Likewise, with 3 years of
follow-up for colonoscopies undertaken in 2001, a total of
602 false-negative tests had occurred. At this time point,
therefore, the PCCRC rate was 10.2%. Identical calculations
were undertaken for each colonoscopy year at 6 month
Table 3 Characteristics of the individuals and cancers occurring within 3 years of a colonoscopy undertaken between 2001 and 2007
Cancers occurring in individuals
>6 months after
colonoscopy
≤ 6 months after
colonoscopy All cancers
Characteristic n % n % n
Median age at diagnosis (IQR) 72 (64–69) 74 (65–81) 72 (64–79)
Sex
Male 2625 8.1 29 755 91.9 32 380
Female 2346 9.2 23 237 90.2 25 583
IMD income category at diagnosis
Most affluent 1009 8.7 10 548 91.3 11 557
2 1101 8.8 11 454 91.2 12 555
3 986 8.0 11 382 92.0 12 368
4 1012 8.6 10 742 91.4 11 754
Most deprived 863 8.9 8866 91.1 9729
Charlson comorbidity score at diagnosis
0 3042 7.5 37 431 92.5 40 473
1 873 10.6 7366 89.4 8239
2 648 10.1 5745 89.9 6393
≥3 408 14.3 2450 85.7 2858
Previous in-patient hospital episode for Crohn’s disease
No 4743 8.3 52 496 91.7 57 239
Yes 228 31.5 496 68.5 724
Previous in-patient hospital episode for ulcerative colitis
No 4392 7.8 51 943 92.2 56 335
Yes 579 35.6 1049 64.4 1628
Previous in-patient hospital episode for diverticular disease
No 2954 7.2 37 971 92.8 40 925
Yes 2017 11.8 15 021 88.2 17 038
Number of colonoscopic investigations in time period
1 4223 7.7 50 669 92.3 54 892
>1 748 24.4 2323 75.6 3071
Dukes’ stage at diagnosis
A 732 9.5 6968 90.5 7700
B 1029 6.3 15 213 93.7 16 242
C 994 7.0 13 178 93.0 14 172
D 686 10.2 6071 89.8 6757
Unknown 1530 11.7 11 562 88.3 13 092
Tumour site
Rectal/sigmoid colon 1897 6.7 26 349 93.3 28 246
Splenic flexure/descending colon 206 7.4 2580 92.6 2786
Transverse colon 276 8.6 2923 91.4 3199
Right colon 1859 9.8 17 916 94.0 19 055
Colon NOS 733 15.7 3944 84.3 4677
Total 4971 8.6 52 992 91.4 57 963
IMD, Index of Multiple Deprivation; NOS, not otherwise specified.
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time intervals and the results of these analyses are shown
in ﬁgure 3.
Overall, the PCCRC rate was 8.6% at 3 years of follow-up
for colonoscopies undertaken between the beginning of 2001
and the end of 2007. Figure 3 illustrates how the PCCRC rate
based on the colonoscopy dataset has changed up to 5 years fol-
lowing colonoscopy during the period of the study. The 5-year
rate fell from 14.2% in 2001 to 8.2% in 2005. The 3-year rate
fell from 10.2% in 2001 to 7.3% in 2007. Finally, the 1-year
rate fell from 3.7% in 2001 to 2.6% in 2009.
Table 4 shows the results of a multivariable analysis investigat-
ing the odds of developing a PCCRC within 3 years of a colon-
oscopy. There was a 6% reduction in the odds of development
of a PCCRC following colonoscopy for each year the study
advanced (OR 0.94, 95% CI 0.93 to 0.95, p<0.01). In contrast,
the risk was increased in women compared with men (OR 1.13,
95% CI 1.06 to 1.20, p<0.01) and in those with previous hos-
pital admissions for Crohn’s disease (OR 2.54, 95% CI 2.11 to
3.06, p<0.01), ulcerative colitis (OR 5.82, 95% CI 5.17 to
6.54, p<0.01) and diverticular disease (OR 1.86, 95% CI 1.75
to 1.98, p<0.01). There was a marked increase in the odds of
developing a PCCRC in individuals who underwent multiple
colonoscopies (OR 2.93, 95% CI 2.71 to 3.15, p<0.01).
DISCUSSION
This is the ﬁrst population-based study investigating the occur-
rence of PCCRC across the English NHS. It has shown that the
PCCRC rate varies considerably in relation to the method used
to deﬁne a PCCRC and the exclusions applied to the dataset.
The application of four previously published methods led to
rates ranging from 2.5% to 7.7% using the same dataset. This
means that published data on PCCRC cannot be used to
compare the quality of colonoscopy between jurisdictions and
rates derived from different methodologies may not be compar-
able.24 Meta-analyses of PCCRC or interval cancers that do not
take account of the different methodologies used to calculate
rates will be ﬂawed.24 To enable comparisons there needs to be
agreement on a single methodology or adjustments need to be
made, as has been done in this study. After adjusting for
Figure 2 Number of colonoscopies
undertaken in the English National
Health Service (NHS) followed by a
diagnosis of cancer within 36 months.
Figure 3 Post-colonoscopy colorectal
cancer (PCCRC) rates over time in the
English National Health Service (NHS).
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differences in methodology, the rates of PCCRC in the English
NHS are similar to those in other countries.
All the previously published methods of calculating PCCRC
are based on a denominator of the number of cancers diagnosed
in a population. To provide patients with a measure focused on
the colonoscopy rather than the cancer, a new method is pre-
sented using colonoscopies as the denominator. The new
method summates detected cancer and PCCRC to provide a
gold standard measure for colonoscopy against which PCCRC
can be compared. Unlike the gold standard of purely diagnostic
tests, this gold standard takes account of the therapeutic cap-
acity of colonoscopy: its ability to prevent, not just detect
cancer. This new approach provides the patient who has a
cancer, or is destined to present with one in the next 3 years,
with a probability the cancer will be missed or not prevented. If
rapidly growing cancers with no precursor lesions exist, this rate
will never become zero. However, with studies demonstrating
that >75% of PCCRCs are either missed or preventable,25 and
with ever improving quality of colonoscopy, it is expected that
future studies will demonstrate the rate of PCCRC (using this
method) could be as low as 1%. This proposed ﬁgure of 1% is
arrived at by ﬁrst assuming that PCCRC rates will fall from the
2007 rate of 7.3% to at least 4%. If more than 75% of
PCCRCs are either missed or preventable, then with an
observed PCCRC rate of 4% we might assume 1% to be
unavoidable. This lowest achievable PCCRC rate would then
represent the ‘inevitable’ rate of cancer following colonoscopy
no matter how well the procedure is done. Patients do not ﬁnd
it difﬁcult to grasp the concept of rapidly growing cancers
(indeed most are surprised at how slowly colorectal cancers
develop). Thus patients are likely to understand that fast
growing cancer is, sometimes, inevitable after a negative colon-
oscopy and ﬁnd acceptable a sensitivity of 99% of either detect-
ing cancer or preventing it developing in the next 3 years.
An alternative denominator of a patient-centric quality
measure to that proposed is all colonoscopies. The resultant sta-
tistics would be of the order of 0.05% or 1:2000 (assuming a
colonoscopy cancer detection rate of 1% and a PCCRC rate of
5%)—a difﬁcult number for patients to grasp compared with
5% or 1:20 for the PCCRC rate using the proposed gold stand-
ard. A further factor to consider is the CI for either measure.
Many thousands of procedures or hundreds of cancers are
required to provide robust estimates of rates.26 Thus reporting
in reasonable timespans (eg, annually) can only occur for pro-
cedure volumes in endoscopy units or across regions or nations;
the sample size will be too small for monitoring performance of
individuals when surrogate measures such as adenoma detection
rate, a good proxy for interval cancer or PCCRC, are an accept-
able alternative.13 27
The new proposed approach yielded a PCCRC rate at 3 years
post colonoscopy of 8.6% in the ﬁrst 7 years of the study
period. The new method allows prospective assessment of
changes in PCCRC rates over time following colonoscopy and
the rates relate to the time the procedures were performed, not
years afterwards. It has demonstrated that in the English NHS,
rates have declined over time with the 3-year rate falling from
10.2% in 2001 to 7.3% in 2007.
This study, as in others, identiﬁed several factors associated
with the development of a PCCRC. A greater proportion of
PCCRCs were found in the right colon.7 10 11 16 28 The under-
lying reasons for this are likely to be multifactorial. For
example, for a colonoscopy to be successful it is important for
the endoscopist to visualise the entire colon and reach the
caecum, but the proximal colon is difﬁcult to reach in some
patients and sometimes the landmarks are unclear so colonosco-
pists may not have reached the caecum even though they think
they have. Furthermore, this portion of the colon is more difﬁ-
cult to cleanse with oral agents, making lesions more difﬁcult to
identify. Finally, a greater proportion of tumours on the
right side of the bowel are associated with microsatellite
instability.29–32 Such tumours are thought to be fast growing
and associated with precursor sessile serrated lesions that can be
difﬁcult to detect at colonoscopy.29 All these factors may, there-
fore, lead to a preponderance of right-sided PCCRC.
The increase in the odds of occurrence of a PCCRC in those
with inﬂammatory bowel disease (IBD) and diverticulosis has
been found in other studies.10 11 16 The increased risk of
PCCRC with IBD may be explained by malignancy being more
difﬁcult to detect in the context of a diseased colon because of
concurrent abnormalities (such as inﬂammatory polyps) and
because cancer in IBD can have a different underlying morph-
ology. Finally, IBD-related cancer may be more aggressive and
develop much quicker. Greater technical difﬁculty performing
the procedure may explain the higher risk of PCCRC in patients
with diverticular disease. These reasons may also explain the
major increase in odds of PCCRC for those undergoing mul-
tiple colonoscopies. Those individuals undergoing multiple
investigations are likely to be under surveillance for an increased
risk of cancer or have experienced an incomplete colonoscopy
Table 4 Odds of the development of a PCCRC within 3 years of a
colonoscopy
Characteristic OR
Lower
95% CI
Upper
95% CI p Value
Year of colonoscopy 0.94 0.93 0.95 <0.01
Sex
Male 1.00
Female 1.13 1.06 1.20 <0.01
Age (per year) 1.00 0.99 1.00 <0.01
IMD income category
Most affluent 1.00
2 1.01 0.92 1.11 0.76
3 0.92 0.84 1.01 0.09
4 0.99 0.90 1.09 0.90
Most deprived 1.01 0.92 1.12 0.79
Previous hospital admission for Crohn’s disease
No 1.00
Yes 2.54 2.11 3.06 <0.01
Previous hospital admission for ulcerative colitis
No 1.00
Yes 5.82 5.17 6.54 <0.01
Previous hospital admission for diverticular disease
No 1.00
Yes 1.86 1.75 1.98 <0.01
Site of tumour
Rectum/sigmoid colon 1.00
Splenic flexure/descending colon 0.98 0.84 1.15 0.82
Transverse colon 1.17 1.02 1.35 0.02
Right colon 1.42 1.32 1.52 <0.01
Colon NOS 2.34 2.13 2.58 <0.01
Number of colonoscopies
in PCCRC/detected category
(per colonoscopy)
2.93 2.71 3.15 <0.01
IMD, Index of Multiple Deprivation; PCCRC, post-colonoscopy colorectal cancer;
NOS, not otherwise specified.
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that needed to be repeated. The strong association of multiple
colonoscopies and the development of a PCCRC is again, there-
fore, not unexpected. These ﬁndings, in keeping with other
studies, emphasise how vigilant the colonoscopist has to be
when colonoscoping these patients. Finally, if PCCRC rates in
patients with bowel disease and in those having repeated colon-
oscopies cannot be improved, patients should be warned of the
greater chance of development of PCCRC.
The main limitations of this study centre on the fact that it is
based upon routine data. This reduces the resolution of the
study. For example, it is not possible to deﬁnitively determine
whether a cancer is truly a PCCRC or a detected cancer but
rather this has to be inferred from the time interval between the
colonoscopy and the date of diagnosis of the tumour. Likewise,
it is not possible to deﬁnitively distinguish between individuals
with and without conditions leaving them at a high risk of
developing cancer or between colonoscopies undertaken as a
part of a surveillance or screening programme and those under-
taken for symptomatic reasons. The National Cancer
Intelligence Network who developed the NCDR recognise these
limitations and are actively seeking to address them by extend-
ing the resource to hold an enhanced cancer registry dataset and
as many routine health datasets as possible. By including infor-
mation from primary care, screening and other similar datasets
it is intended its scope will be increased to capture more
detailed information about the patient, their colonoscopy and
the reasons behind it. This will strengthen the new methodology
proposed and address these limitations.
This study is based on the data held within the NCDR.20 This
resource holds population-based data on individuals diagnosed
with cancer in England and the routine and administrative nature
of these datasets does, unfortunately, pose some limitations. For
example, the quality and accuracy of the Hospital Episode
Statistics (HES) component of the NCDR (from which the colon-
oscopy information has been derived) has been questioned, and
for colorectal cancer there are around 8% more cancers listed in
this dataset than are identiﬁed by cancer registries (personal com-
munication NCIN). As the National Cancer Registration Service
over this time period has a proven ascertainment rate of >98%33
this would suggest that there is signiﬁcant miscoding in HES
(perhaps as a result of the suspicion of cancer rather than con-
ﬁrmed cancer) and relying on this resource alone to identify
PCCRC would overestimate the rate. This study has, however,
relied on linked data and this linkage has ensured the accuracy of
the cancer diagnosis. Furthermore, comparisons of the informa-
tion held in HES to that collected by clinical trials suggests that
agreement is good for cases of conﬁrmed cancer.35 As a result,
such linked data will provide the most robust ﬁgures possible.
Another limitation of the NCDR is that, currently, it only
contains information on colonoscopies in individuals who go on
to be diagnosed with cancer. As the clinical thresholds for use
of colonoscopy and the incidence of colorectal cancer vary
across the country, the optimal method of assessing the sensitiv-
ity and speciﬁcity of colonoscopy would include all colonos-
copies rather than just those that led to cancer. Furthermore,
high-quality colonoscopy can also reduce the incidence of the
disease by the identiﬁcation and removal of any precancerous
lesions. The most robust method to assess PCCRC rates would
be to incorporate information on all colonoscopies undertaken
in the NHS, rather than just those in individuals who subse-
quently went on to be diagnosed with cancer.
Although colonoscopy is the main diagnostic investigation for
colorectal cancer, ﬂexible sigmoidoscopy is also commonly used
in England. This technique allows visualisation of the bowel up
to the splenic ﬂexure and its adoption has been shown to
reduce the incidence of left-sided lesions and reduce mortality
from colorectal cancer.36 It is now being assessed within the
NHS Bowel Cancer Screening Programme. These analyses do
not take into account the use of this technique but rather focus
solely on colonoscopy. Further work is required, therefore, to
assess the PCCRC rate of ﬂexible sigmoidoscopy.
In conclusion, this study has demonstrated that the method
used to determine PCCRC rate signiﬁcantly affects ﬁndings,
thus international benchmarking requires an agreed method for
calculating PCCRC. The new method proposed uses colonos-
copy as the denominator and its application demonstrates
PCCRC rates are falling with time in the English NHS.
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